Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 5, 2005 - Issue 5
Submit an article Journal homepage
151
Views
8
CrossRef citations to date
0
Altmetric
Drug Profile

Rizatriptan in migraine

Abouch Valenty Krymchantowski Instituto de Neurologia Deolindo Couto, Av das Americas 1155/1608 Barra Rio de Janeiro, Brazil. [email protected]
&
Marcelo Eduardo Bigal The Albert Einstein College of Medicine, NY, The New England Center for Headache, Stamford, Connecticut, USA. [email protected]
Pages 597-603 | Published online: 10 Jan 2014

References

  • Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231–238 (1996).
  • Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology 44(Suppl. 14), S24–S39 (1994).
  • Rasmussen BK. Epidemiology of Headache. Cephalalgia 15, 45–68 (1995).
  • Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1–13 (1997).
  • Saxena P, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA. 411–438 (2000).
  • Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18–22 (1998).
  • Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 44(7), 661–668 (2004).
  • Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan – nonresponders: a survey in 366 migraine patients. Headache 36, 471–475 (1996).
  • Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21–28 (1995).
  • Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46–51 (1996).
  • Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurology 4(1), 10 (2004).
  • Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol.55(1), 19–26 (2004).
  • Maxalt® (rizatriptan) tablets. In: Physicians Desk Reference®. 53rd Edition, Medical Economics Company, NJ, USA. 1822–1827 (1999).
  • Hargreaves RJ, Longmore J, Beer M et al. The pharmacology and mechanisms of action of rizatriptan. In: Drug Treatment of Migraine and Other Headaches Diener HC (Ed.). Karger, Basel, Switzerland. Monogr. Clin. Neurosci. 17, 141–161 (2000).
  • De Voogd JM, Prager G. Early clinical experience with flesinoxan, a new selective 5-HT1A receptor agonist. In: Cardiovascular Pharmacology of 5-Hydroxytriptamine. Saxena PR, Wallis DA, Wouters W, Bevan P (Eds). Kluwer Academic Publishers, London, UK. 355–359 (1990).
  • Siedelin KN, Tfelt-Hansen P, Mendel CN, Stepanavage M. Peripheral hemodynamic study of MK-462, ergotamine, and their combination in humans. Cephalalgia 15(Suppl. 14), 207 (2000).
  • Sciberras DG, Polvino WJ, Gertz BJ et al. Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br. J. Clin. Pharmacol. 4349–4354 (1995).
  • Lee Y, Conroy JA, Stepanavage ME et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br. J. Clin. Pharmacol. 47, 373–378 (1999).
  • Cutler NR, Jhee SS, Majumdar AK et al. Pharmacokinetics of rizatriptan tablets during and between migraine attacks. Headache 39, 264–269 (1999).
  • Goldberg MR, Lee Y, Ermlich S et al. Single and multiple-dose pharmacokinetics and tolerability of rizatriptan, a novel 5-HT1B/1D agonist for migraine. Headache 37, 310 (1997).
  • IHS Committee on Clinical Trials in Migraine. Guidelines for controlled trials in migraine. Cephalalgia 11, 1–12 (1991).
  • Gjsman H, Kramer MS, Sargent J et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17, 647–651 (1997).
  • Teall J, Tuchman M, Cutler N et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, out-patient study. Headache 38, 281–287 (1998).
  • Tfelt-Hansen P, Teall J, Rodriguez F et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 38, 748–755 (1998).
  • Kramer MS, Matzura-Wolfe D, Polis A et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 51, 773–781 (1998).
  • Dahlof C, Lines C. Rizatriptan – therapy. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.). Karger, Basel, Switzerland. 17, 162–172 (2000).
  • Ahrens SP, Farmer MV, Williams DL et al. and the Rizatriptan Wafer Protocol 049 Study Group. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 19, 525–530 (1999).
  • Klapper JA, O’Connor S. Rizatriptan wafer-sublingual vs. placebo at the onset of acute migraine. Cephalalgia 20, 585–587 (2000).
  • Ferrari MD, Roon K, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute treatment : a meta-analysis of 53 trials. Lancet 358, 1668–1675 (2001).
  • Dahlof C, Lipton RB, McCarroll KA et al. Within-patient consistency of response of rizatriptan fro treating migraine. Neurology 55, 1511–1516 (2000).
  • Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur. Neurol. 49, 20–29 (2003).
  • Lines C, Visser WH, Vandormael K, Reines SA. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache 37, 319–320 (1997).
  • Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Efficacy and safety of rizatriptan versus standard care during long-term treatment of migraine. Headache 38, 764–771 (1998).
  • Dodick D, Lipton RB, Martin V et al. Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 44(5), 414–425 (2004).
  • Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62, 563–568 (2004).
  • Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39, S20–S26 (1999).
  • Diener HC. Eletriptan in migraine. Expert Rev. Neurotherapeutics 5(1), 43–53 (2005).
  • Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: a retrospective analysis of data from three clinical trials. Clin. Ther. 22, 1035–1048 (2000).
  • Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurologia 28(4), 1–4 (2004).
  • Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib versus rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309–312 (2002).
  • Krymchantowski AV, Bigal ME, Moreira PF. Rizatriptan versus rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Neurology 64(Suppl. 1), A348 (2005) (Abstract).
  • Krymchantowski AV. Combining therapies for the treatment of migraine: is there a role? Expert Rev. Neurotherapeutics 5(2), 145–147 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.